The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
MuradA.M.Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology (Williston Park).2003; 17(12 suppl 14): 26–32.
2.
O'ShaughnessyJ., NagS., Calderillo-RuizG.. Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol.2003 (abstract 25). Available at: www.asco.org. Accessed April 17, 2007.
3.
AlbainK.S., NagS., Calderillo-RuizG.. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol2004 (abstract 510). Available at: www.asco.org. Accessed April 17, 2007.
4.
DelfinoC., CacciaG., GonzalesL.R.. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Oncology.2004; 66: 18–23.
5.
DemirayM., KurtE., EvrenselT.. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure. Cancer Invest.2005; 23: 386–391.
6.
AllouacheD., GawandeS.R., Tubiana-HulinM.. First-line therapy with gemcitabine and paclitaxel in locally recurrent or metastatic breast cancer: a phase II study. BMC Cancer.2005; 5: 151–159.
7.
ColomerR., LlombartA., LluchA.. Proc Am Soc Clin Oncol.2000 (abstract 373). Available at: www.asco.org. Accessed April 17, 2007.
8.
AlexopoulosA., KaramouzisM.V., IoannidisG.. Salvage treatment with biweekly administration of paclitaxel (P) and gemcitabine (G) in patients (pts) with metastatic breast cancer (MBC) heavily pretreated with anthracycline and docetaxel containing regimens. Proc Am Soc Clin Oncol.2005 (abstract 836). Available at: www.asco.org. Accessed April 17, 2007.
9.
ViciP., CapomollaE., FoggiP.. High activity of salvage treatment with biweekly paclitaxel -gemcitabine combination in heavily pretreated breast cancer patients. J Exp Clin Cancer Res.2006; 25: 39–44.
10.
TomaoS., RomitiA., TomaoF.. A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. BMC Cancer.2006; 6: 137–141.
11.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer. v.1.2007. Available at: http://www.nccn.org/. Accessed April 17, 2007.
12.
ColomerR.What is the best schedule for administration of gemcitabinetaxane?Cancer Treat Rev.2005; 31(Suppl 4): S23–S28.
13.
SuiM., XiongX., KraftA.S., FanW.Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther.2006; 5: 1015–1021.
14.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
15.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - antiemesis. V.1.2007. Available at: http://www.nccn.org/. Accessed April 17, 2007.
16.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
17.
Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. 2005. Available at: http://www.mascc.org/. Accessed April 17. 2007.
18.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
19.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
20.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
21.
de WitR., de BoerA.C., LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85: 1099–1101.
22.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
23.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
27.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - myeloid growth factors. v.1.2007. Available at: http://www.nccn.org/. Accessed April 17, 2007.
28.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2003; 35: 57–74.
29.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
30.
DelalogeS., LlombartA., Di PalmaM.. Gemcitabine in patients with solid tumors and renal impairment. Am J Clin Oncol.2004; 27: 289–293.
31.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
